Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT.
Autor: | Passweg JR; EBMT Activity Survey Office, Hematology Division, University Hospital, Basel, Switzerland., Baldomero H; EBMT Activity Survey Office, Hematology Division, University Hospital, Basel, Switzerland. helen.baldomero@usb.ch., Ciceri F; Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy., de la Cámara R; Hematology Department, Hospital Universitario de la Princesa, Madrid, Spain., Glass B; Klinik für Hämatologie und Stammzelltransplantation, HELIOS Klinikum Berlin-Buch, Berlin, Germany., Greco R; Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy., Hazenberg MD; Department of Hematology, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, The Netherlands., Kalwak K; Clinical Department of Pediatric BMT, Hematology and Oncology, Wroclaw Medical University, Wroclaw, Poland., McLornan DP; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK., Neven B; Pediatric immune-hematology unit, Necker Children Hospital, Assistance Publique Hôpitaux de Paris, Paris, France., Perić Z; School of Medicine, University of Zagreb, University Hospital Center Zagreb, Zagreb, Croatia., Risitano AM; Hematology and Hematopoietic Transplant Unit, Azienda Ospedaliera di Rilievo Nazionale 'San Giuseppe Moscati' (A.O.R.N. Giuseppe Moscati), Avellino, Italy., Ruggeri A; Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy., Snowden JA; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Sureda A; Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain. |
---|---|
Jazyk: | angličtina |
Zdroj: | Bone marrow transplantation [Bone Marrow Transplant] 2024 Jun; Vol. 59 (6), pp. 803-812. Date of Electronic Publication: 2024 Mar 04. |
DOI: | 10.1038/s41409-024-02248-9 |
Abstrakt: | In 2022, 46,143 HCT (19,011 (41.2%) allogeneic and 27,132 (58.8%) autologous) in 41,854 patients were reported by 689 European centers. 4329 patients received advanced cellular therapies, 3205 of which were CAR-T. An additional 2854 patients received DLI. Changes compared to the previous year were an increase in CAR-T treatments (+27%) and decrease in allogeneic (-4.0%) and autologous HCT (-1.7%). Main indications for allogeneic HCT were myeloid malignancies (10,433; 58.4%), lymphoid malignancies (4,674; 26.2%) and non-malignant disorders (2572; 14.4%). Main indications for autologous HCT were lymphomas (7897; 32.9%), PCD (13,694; 57.1%) and solid tumors (1593; 6.6%). In allogeneic HCT, use of sibling donors decreased by -7.7%, haploidentical donors by -6.3% and unrelated donors by -0.9%. Overall cord blood HCT decreased by -16.0%. Use of allogeneic, and to a lesser degree autologous HCT, decreased for lymphoid malignancies likely reflecting availability of new treatment modalities, including small molecules, bispecific antibodies, and CAR-T cells. Pediatric HCT activity remains stable (+0.3%) with differences between allogeneic and autologous HCT. Use of CAR-T continues to increase and reached a cumulative total of 9039 patients treated with wide differences across European countries. After many years of continuous growth, increase in application of HCT seems to have slowed down. (© 2024. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: |